They have the money to get this approved and want a drug to treat DME as none has been approved in the U.S. to date.Shareholders are setting real well at this point.
Sell the drug to Allergan or Partner as Credit Suisse securities analyst stated today and Lisa Douglas at Alimera should of read.They are talking with a Partner in report submitted thru Midnight Rider today.
volume picking up...this news will rocket alim...news after the close would be nice!
It was reported by Credit Suisse which now were hearing from a former employee it's a company in Europe he's been heard guys talking about.I won't be selling just adding to position.
what's does that mean? "Alergan made the offer"?
Means a possible buyout and would surely be above cash value, so probably at least $3 a share.
Called Alimera and they said they could not confirm,nor deny offer was recieved.This will be interesting now this week.